BR112018016629A2 - moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 - Google Patents
moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4Info
- Publication number
- BR112018016629A2 BR112018016629A2 BR112018016629A BR112018016629A BR112018016629A2 BR 112018016629 A2 BR112018016629 A2 BR 112018016629A2 BR 112018016629 A BR112018016629 A BR 112018016629A BR 112018016629 A BR112018016629 A BR 112018016629A BR 112018016629 A2 BR112018016629 A2 BR 112018016629A2
- Authority
- BR
- Brazil
- Prior art keywords
- muscarinic acetylcholine
- positive allosteric
- allosteric modulators
- compounds
- acetylcholine receptor
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title abstract 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title abstract 2
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- MDIJJBLRSFWMIZ-UHFFFAOYSA-N 2,4-dimethylquinoline-6-carboxamide Chemical class C1=C(C(N)=O)C=CC2=NC(C)=CC(C)=C21 MDIJJBLRSFWMIZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435426P | 2016-12-16 | 2016-12-16 | |
| PCT/US2017/066608 WO2018112312A1 (en) | 2016-12-16 | 2017-12-15 | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016629A2 true BR112018016629A2 (pt) | 2018-12-26 |
Family
ID=62559292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016629A BR112018016629A2 (pt) | 2016-12-16 | 2017-12-15 | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10934276B2 (enExample) |
| EP (1) | EP3558946A4 (enExample) |
| JP (1) | JP7016471B2 (enExample) |
| CN (1) | CN110035995A (enExample) |
| BR (1) | BR112018016629A2 (enExample) |
| MA (1) | MA47127A (enExample) |
| WO (1) | WO2018112312A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164459B (zh) | 2018-09-28 | 2024-09-03 | 詹森药业有限公司 | 单酰基甘油脂肪酶调节剂 |
| AU2019462140A1 (en) * | 2019-08-21 | 2022-02-24 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| ES3037365T3 (en) | 2019-09-30 | 2025-10-01 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN114805252B (zh) * | 2022-04-29 | 2024-01-30 | 上海交通大学医学院 | 一种用于精神分裂症认知功能障碍治疗的萘基酰胺类化合物及其制备方法和应用 |
| CN115246842B (zh) * | 2022-06-15 | 2024-05-24 | 深圳湾实验室 | 一类靶向去泛素化酶usp25和usp28的小分子抑制剂 |
| CN120025315B (zh) * | 2024-09-29 | 2025-09-05 | 宜昌人福药业有限责任公司 | 一种苯并六元杂环酰胺类化合物、药物组合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10156719A1 (de) * | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| EP1809290A2 (en) * | 2004-11-03 | 2007-07-25 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
| TWI384949B (zh) | 2006-12-01 | 2013-02-11 | 含有以喹啉化合物或其鹽為有效成分之土壤處理劑或種子處理劑、與使用彼等之植物病害之防治方法 | |
| BRPI0818633A2 (pt) * | 2007-10-15 | 2015-04-07 | Sumitomo Chemical Co | Compostos de n-benzil quinolina 6-carboxamida e método de controle de doença de planta usando os mesmos |
| BR112014031896A2 (pt) * | 2012-06-20 | 2017-06-27 | Univ Vanderbilt | composto, composição farmacêutica, e, método para o tratamento de um distúrbio |
| EP3233087B1 (en) * | 2014-12-16 | 2019-10-02 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
-
2017
- 2017-12-15 EP EP17880820.0A patent/EP3558946A4/en not_active Withdrawn
- 2017-12-15 JP JP2019532081A patent/JP7016471B2/ja not_active Expired - Fee Related
- 2017-12-15 WO PCT/US2017/066608 patent/WO2018112312A1/en not_active Ceased
- 2017-12-15 US US16/469,972 patent/US10934276B2/en active Active
- 2017-12-15 BR BR112018016629A patent/BR112018016629A2/pt not_active Application Discontinuation
- 2017-12-15 CN CN201780073095.1A patent/CN110035995A/zh active Pending
- 2017-12-15 MA MA047127A patent/MA47127A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200079756A1 (en) | 2020-03-12 |
| CN110035995A (zh) | 2019-07-19 |
| MA47127A (fr) | 2019-10-30 |
| WO2018112312A1 (en) | 2018-06-21 |
| EP3558946A4 (en) | 2020-05-27 |
| EP3558946A1 (en) | 2019-10-30 |
| US10934276B2 (en) | 2021-03-02 |
| JP7016471B2 (ja) | 2022-02-07 |
| JP2020503302A (ja) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018016629A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 | |
| PH12018501731A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | |
| GEP20207167B (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| CL2016002661A1 (es) | Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy. | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| CL2018002697A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos. | |
| BR112022006686A2 (pt) | Antagonistas de receptor muscarínico de acetilcolina m1 | |
| CL2019001129A1 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y. | |
| WO2019089676A8 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| BR112016025423A2 (pt) | compostos e composições como agonistas de receptores do tipo toll 7 | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| EP4628094A3 (en) | BAFF-R ANTIBODIES AND THEIR USES | |
| NZ737399A (en) | Ccr2 modulators | |
| BR112018013882A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 | |
| MX2022003907A (es) | Compuestos y composiciones y usos de los mismos. | |
| MX388562B (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| BR112018013879A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| EA202090414A1 (ru) | Соединения и их применение | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |